Aspiro Therapeutics to Participate in RESI San Diego 2026

Tucson, Arizona | June 2, 2026 – Aspiro Therapeutics will participate in RESI San Diego 2026, one of the leading partnering conferences for early-stage life science companies, bringing together biotechnology innovators, investors, strategic partners, and industry leaders to accelerate the development of innovative healthcare technologies.

During the conference, Chief Executive Officer and Co-Founder James Lovgren will meet with venture capital firms, strategic investors, and potential partners to discuss Aspiro’s progress advancing ATX-1019, the company’s first-in-class inhaled peptidomimetic therapy inspired by the protective biology of CC16.

The conference provides an opportunity to introduce Aspiro’s approach to developing disease-modifying therapies for obstructive lung diseases such as asthma and COPD while expanding relationships within the life sciences investment and partnering community.

Aspiro Therapeutics looks forward to engaging with investors and strategic partners as the company continues to advance ATX-1019 through preclinical development toward IND-enabling studies.

Learn more about RESI San Diego